• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

EBioMedicine . Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity

tetano

Editor, Senior Moderator
EBioMedicine


. 2020 Jul 22;58:102911.
doi: 10.1016/j.ebiom.2020.102911. Online ahead of print.
Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity


Siti Naqiah Amrun[SUP] 1 [/SUP], Cheryl Yi-Pin Lee[SUP] 2 [/SUP], Bernett Lee[SUP] 3 [/SUP], Siew-Wai Fong[SUP] 4 [/SUP], Barnaby Edward Young[SUP] 5 [/SUP], Rhonda Sin-Ling Chee[SUP] 1 [/SUP], Nicholas Kim-Wah Yeo[SUP] 1 [/SUP], Anthony Torres-Ruesta[SUP] 6 [/SUP], Guillaume Carissimo[SUP] 1 [/SUP], Chek Meng Poh[SUP] 1 [/SUP], Zi Wei Chang[SUP] 1 [/SUP], Matthew Zirui Tay[SUP] 1 [/SUP], Yi-Hao Chan[SUP] 1 [/SUP], Mark I-Cheng Chen[SUP] 7 [/SUP], Jenny Guek-Hong Low[SUP] 8 [/SUP], Paul A Tambyah[SUP] 9 [/SUP], Shirin Kalimuddin[SUP] 8 [/SUP], Surinder Pada[SUP] 10 [/SUP], Seow-Yen Tan[SUP] 11 [/SUP], Louisa Jin Sun[SUP] 12 [/SUP], Yee-Sin Leo[SUP] 13 [/SUP], David C Lye[SUP] 13 [/SUP], Laurent Renia[SUP] 1 [/SUP], Lisa F P Ng[SUP] 14 [/SUP]



Affiliations

Abstract

Background: Given the unceasing worldwide surge in COVID-19 cases, there is an imperative need to develop highly specific and sensitive serology assays to define exposure to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Methods: Pooled plasma samples from PCR positive COVID-19 patients were used to identify linear B-cell epitopes from a SARS-CoV-2 peptide library of spike (S), envelope (E), membrane (M), and nucleocapsid (N) structural proteins by peptide-based ELISA. Hit epitopes were further validated with 79 COVID-19 patients with different disease severity status, 13 seasonal human CoV, 20 recovered SARS patients and 22 healthy donors.
Findings: Four immunodominant epitopes, S14P5, S20P2, S21P2 and N4P5, were identified on the S and N viral proteins. IgG responses to all identified epitopes displayed a strong detection profile, with N4P5 achieving the highest level of specificity (100%) and sensitivity (>96%) against SARS-CoV-2. Furthermore, the magnitude of IgG responses to S14P5, S21P2 and N4P5 were strongly associated with disease severity.
Interpretation: IgG responses to the peptide epitopes can serve as useful indicators for the degree of immunopathology in COVID-19 patients, and function as higly specific and sensitive sero-immunosurveillance tools for recent or past SARS-CoV-2 infections. The flexibility of these epitopes to be used alone or in combination will allow for the development of improved point-of-care-tests (POCTs).
Funding: Biomedical Research Council (BMRC), the A*ccelerate GAP-funded project (ACCL/19-GAP064-R20H-H) from Agency of Science, Technology and Research (A*STAR), and National Medical Research Council (NMRC) COVID-19 Research fund (COVID19RF-001) and CCGSFPOR20002. ATR is supported by the Singapore International Graduate Award (SINGA), A*STAR.

Keywords: Biomarkers; COVID-19; Epitopes; Patients; SARS-CoV-2.
 
Back
Top Bottom